Patent litigation between Teva and Amgen Inc. has been dismissed, the Company disclosed in its August 8, 2011 Form 10-Q filing with the U.S. Securities and Exchange Commission for the…
Patent litigation between Teva and Amgen Inc. relating to Neutroval(TM) (a recombinant form of human G-CSF) has been settled, Amgen disclosed in its August 8, 2011, Form 10-Q filing with…
A trial date has yet to be set for Amgen Inc.’s G-CSF patent litigation with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.
Following the August 13, 2010 hearing, on…
The U.S. Court of Appeals for the Federal Circuit, on June 1, 2009, affirmed the U.S. District Court for the District of Delaware’s ruling on claim construction and non-infringement in…
Human Genome Sciences and Amgen Inc. seek to stay an action to review a decision on priority and judgment by the Board of Patent Appeals and Interference in the U.S.…
F. Hoffmann-La Roche Ltd.’s appeal from the U.S. District Court for the District of Massachusetts’ final judgment in Amgen Inc.’s lawsuit alleging infringement of its erythropoietin patents remains pending with…
No decision has been issued on either the motion for a stay or the motion to terminate the investigation involving Roche Diagnostics GmbH and Amgen Inc.
The U.S. Court of Appeals…
Amgen Inc. faces a patent infringement suit by Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc in the U.S. District Court for the Eastern District of Pennsylvania.
On May 20,…
A claims construction hearing in Amgen Inc.’s patent infringement lawsuit against Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Barr Laboratories, Inc. is set for Jan. 25 and Jan.…
Oral argument on Ariad Pharmaceuticals Inc.’s appeal from the U.S. District Court for the District of Delaware’s patent infringement ruling in favor of Amgen Inc. remains to be scheduled.
On April…